Related references
Note: Only part of the references are listed.Rescue of multiple class II CFTR mutations by elexacaftor plus tezacaftor plus ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
Onofrio Laselva et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Discovery of CFTR modulators for the treatment of cystic fibrosis
Miqueias Lopes-Pacheco et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment
Valeria Capurro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Miqueias Lopes-Pacheco
FRONTIERS IN PHARMACOLOGY (2020)
Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR
Miqueias Lopes-Pacheco et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
Guido Veit et al.
JCI INSIGHT (2020)
R560S: A class II CFTR mutation that is not rescued by current modulators
Nikhil T. Awatade et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Harry G. M. Heijerman et al.
LANCET (2019)
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
P. G. Middleton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A novel triple combination of pharmacological chaperones improves F508del-CFTR correction
Graeme W. Carlile et al.
SCIENTIFIC REPORTS (2018)
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Steven M. Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Jennifer L. Taylor-Cousar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Combination of Correctors Rescues CFTR Transmembrane-Domain Mutants by Mitigating their Interactions with Proteostasis
Miqueias Lopes-Pacheco et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Correctors Rescue CFTR Mutations in Nucleotide-Binding Domain 1 (NBD1) by Modulating Proteostasis
Miqueias Lopes-Pacheco et al.
CHEMBIOCHEM (2016)
Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis
Johanna F. Dekkers et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis
Miqueias Lopes-Pacheco
FRONTIERS IN PHARMACOLOGY (2016)
Combination of Correctors Rescue ΔF508-CFTR by Reducing Its Association with Hsp40 and Hsp27
Miqueias Lopes-Pacheco et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
C. E. Wainwright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery
Hugo M. Botelho et al.
SCIENTIFIC REPORTS (2015)
Rescue of NBD2 Mutants N1303K and S1235R of CFTR by Small-Molecule Correctors and Transcomplementation
Daniele Rapino et al.
PLOS ONE (2015)
Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR
Carlos M. Farinha et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function
Fredrick Van Goor et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
Revertants, Low Temperature, and Correctors Reveal the Mechanism of F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction
Carlos M. Farinha et al.
CHEMISTRY & BIOLOGY (2013)
Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein
Lihua He et al.
FASEB JOURNAL (2013)
Ouabain mimics low temperature rescue of F508del-CFTR in cystic fibrosis epithelial cells
Donglei Zhang et al.
FRONTIERS IN PHARMACOLOGY (2012)
Mechanisms of CFTR folding at the endoplasmic reticulum
Soo Jung Kim et al.
FRONTIERS IN PHARMACOLOGY (2012)
Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling
Elvira Sondo et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2011)
Influence of cell background on pharmacological rescue of mutant CFTR
Nicoletta Pedemonte et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2010)
The Cystic Fibrosis-causing Mutation ΔF508 Affects Multiple Steps in Cystic Fibrosis Transmembrane Conductance Regulator Biogenesis
Patrick H. Thibodeau et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Enhanced cell-surface stability of rescued ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones
Karoly Varga et al.
BIOCHEMICAL JOURNAL (2008)
Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms
Monica Roxo-Rosa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains
P Vergani et al.
NATURE (2005)
Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes
M Sharma et al.
JOURNAL OF CELL BIOLOGY (2004)
COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code
XD Wang et al.
JOURNAL OF CELL BIOLOGY (2004)
Efficient intracellular processing of the endogenous cystic fibrosis transmembrane conductance regulator in epithelial cell lines
K Varga et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Conformational and temperature-sensitive stability defects of the ΔF508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments
M Sharma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)